EASL Index of links
This page was last updated on April 23, to view a summary of the meeting with new updates click here.
EASL updates throughout the meeting are available on the blog by Clicking here.
Summary Of The 47th European Association for the Study of the Liver EASL
April 24-Summary continues to be updated
The promise of all oral hepatitis C drug regimens were the highlight of the liver conference this year. For the hepatitis C patient the drug developments in Interferon-free regimes will become the long awaited revolution in HCV treatment.........
Bristol-Myers Squibb’s - Daclatasvir (BMS-790052) and NS3 Protease Inhibitor Asunaprevir (BMS-650032)
April 19-20
Slides @ NATAP-
Dual Oral Therapy with NS5A Inhibitor Daclatasvir (BMS-790052) and NS3 Protease Inhibitor Asunaprevir (BMS-650032) in HCV Genotype 1b-Infected Null Responders or Patients Ineligible/Intolerant to Peginterferon/Ribavirin -
Daclatasvir BMS-790052 Plus Peg/Ribavirin
Update April 22
EASL Poster - A description OF virologic escape in HCV genotype 1-infected PATIENTS treated with Daclatasvir (BMS-790052) IN COMBINATION WITH ribavirin and PEGINTERFERON ALFA-2A or PegINTERFERON ALFA-2B
View Abstract
EASL Poster - TRIPLE THERAPY WITH DACLATASVIR (DCV; bms-790052), PEGINTERFERON ALFA-2A AND RIBAVIRIN IN HCV-INFECTED PRIOR NULL AND PARTIAL RESPONDERS: 12-WEEK RESULTS OF PHASE 2B COMMAND-2 TRIAL
View Abstract
Headlines
Results add to data suggesting that SVR can be achieved with the combination of daclatasvir (BMS-790052) and asunaprevir (BMS-650032) in HCV genotype 1b patients
On The Blog
EASL-All-Oral Hepatitis C Treatment with Investigational Compounds Daclatasvir and Asunaprevir Achieved Sustained Virologic Response in 77% of Difficult-to-Treat Patients
Daclatasvir from Bristol-Myers Squibb and Gilead's GS-7977
April 19-20
Slides @ NATAP-
Potent Viral Suppression With the All-Oral Combination of Daclatasvir (NS5A Inhibitor) and GS-7977 (Nucleotide NS5B Inhibitor), +/- Ribavirin, in Treatment-Naive Patients With Chronic HCV GT1, 2, or 3 (100% SVR gt1, 91% gt2)
EASL Poster-
POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/-RIBAVIRIN, IN TREATMENT-NAÏVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3
HIV and Hepatitis
EASL: GS-7977, Daclatasvir, and Asunaprevir Look Good in Interferon-Free Regimens
Headlines
Gilead Rises After Hepatitis Data Open New Test Options
All-Oral Combination of Investigational Hepatitis C (HCV) Compounds Daclatasvir and GS-7977 Achieved Sustained Virologic Response (SVR4) in 100% of Genotype 1 and 91% of Genotype 2 and 3 Treatment-Naïve Patients in Phase II Study
Dramatic data for Gilead, Bristol hepatitis C drugs
Gilead, Bristol-Myers Report Positive Viral Responses In Hepatitis C Studies
Gilead-Bristol-Myers hep C regimen promising
Combination Of Gilead, Bristol-Myers Hepatitis C Drugs Show Promise In Study
Have BMS and Gilead found the 'killer app' for hep. C?
On The Blog
EASL-All Oral Combo Daclatasvir and GS-7977=100% SVR Geno 1 and 91% SVR Geno 2 and 3
Gilead Sciences - GS-7977 Plus Ribavirin
April 19-20
On The Blog
EASL-Early SVR Rates for GS-7977 Plus Ribavirin in Geno 1 Treatment-Naïve Hepatitis C Patients
Update April 22
Once Daily GS-7977 Plus Ribavirin in HCV Genotypes 1-3: The ELECTRON Trial -
EASL Poster
ELECTRON: ONCE DAILY PSI-7977 PLUS RBV IN HCV GT1/2/3
Gilead Sciences - GS-7977 in combination with PEG-IFN and ribavirin
April 19-20
Slides @ NATAP
Update April 21
GS-7977 + PEG/RBV in HCV Genotype 1: The ATOMIC Trial An End To Response-Guided Therapy
GS-7977 Phase 2 Trials: Concordance of SVR4 with SVR12 and SVR24 in HCV Genotypes 1-3 -Proton, Electron, Atomic- Twelve weeks of GS-7977 Alone Or In Combination with ribavirin and/or PEG-IFN -
EASL Poster
PSI-7977 PROTON and ELECTRON: 100% CONCORDANCE OF SVR4 WITH SVR24 IN HCV GT1, GT2, & GT3y
EASL Poster -Virological analysis of HCV genotype 1 patient samples from the proton study
View Abstract
Headlines
Promising New Hepatitis C Treatment Tested at Virginia Mason
On The Blog
EASL-GS-7977 SVR Data for 12-Week Regimen of GS-7977 Plus Peg and Ribavirin in Geno 1
Gilead - GS-5885, GS-9451, GS-9190-(tegobuvir) Plus Ribavirin
April 22
Slides @ NATAP
Interim Sustained Virologic Response Rates in Treatment-Naïve HCV Genotype 1a and 1b Patients Treated for 12 or 24 Weeks with an Interferon-Free All-Oral Quad Regimen
Resistance GS-5885
EASL Poster - ANTIVIRAL ACTIVITY AND RESISTANCE PROFILE OF THE NOVEL HCV NS5A INHIBITOR GS-5885
View Abstract
Headlines
April 18
Gilead Sciences to Present New Hepatitis B and C Data at European Conference on Liver Disease This Week
Vertex-Telaprevir
April 19-20
Telaprevir-Resistant Viral Variants
EASL Poster - DEEP SEQUENCING SCREENING FOR TELAPREVIR-RESISTANT VIRAL VARIANTS IN PREVIOUS NULL RESPONDERS FAILS TO IDENTIFY THOSE PATIENTS AT RISK OF FAILING TELAPREVIR PLUS PEGINTERFERON/RIBAVIRIN THERAPY
View Abstract
Headlines
J&J Open to Expanding Hepatitis C Cooperation With Vertex
Vertex (VRTX) Reports Encouraging Data from Phase 2 PROVE 2 of INCIVEK; Begins Enrollment in Phase 2b
On The Blog
Vertex Update-Plans enrollment for Phase 2b study all-oral (interferon-free) treatment regimen
EASL-Drug interactions won't exclude HCV transplant or HIV co-infected patients from treatment
Merck - Boceprevir
April 19-20
Slides @ NATAP
Update April 23
Sustained Virologic Response (SVR) in Prior PegInterferon/Ribavirin (PR) Treatment Failures After Retreatment with Boceprevir (BOC) + PR: PROVIDE Study Interim Results -
Headlines
Two strategies for managing anemia in hepatitis C patients work equally well, Merck says
Merck Reports Phase III Results With Vicrelis - Anemia management on viral response evaluated in Hepatitis C patients
Victrelis Shows Effectiveness for Prior Treatment Null Responders
On The Blog
EASL-Anemia Management Strategies Used With VICTRELIS® (boceprevir) Combination Therapy
Telaprevir and Boceprevir
HIV and Hepatitis
Update April 21
EASL: Telaprevir and Boceprevir Effective but Cause Serious Side Effects in Patients With Cirrhosis
Headlines
April 19-20
Telaprevir and boceprevir show high rate of serious side-effects in hepatitis C patients with urgent need of treatment
Telaprevir and VX-222
April 22
EASL-Poster - Characterization of HCV Variants in Genotype 1 Treatment-naïve Patients Administered the Combination of TVR and VX-222 in DUAL arms of ZENITH study
View Abstract
EASL Poster-All IL28B Genotypes Have High SVR Rates in Patients Treated with VX-222 in Combination with Telaprevir/Peginterferon/Ribavirin in the ZENITH Study
View Abstract
Achillion - ACH-1625, ACH-3102 and ACH-2928
ACH-1625
EASL Poster - CHARACTERIZATION OF HCV NS3 PROTEASE VARIANTS FROM PATIENTS ENROLLED IN A 28-DAY PHASE 2A TRIAL OF ACH-1625 DAILY DOSING PLUS PEGIFN-ALPHA 2A/RBV
View Abstract
On The Blog
Update April 23
EASL-Achillion Clarifies End of Treatment Data From Phase 2a Trial With ACH-1625 Based Regimen in Hepatitis C
Update-April 21
EASL-100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C
Novartis' hepatitis drug alisporivir on hold
April 19-20
Headlines
Novartis halts hepatitis drug trial after death
Novartis: Experimental Hepatitis C Drug Development On Hold
Patient dies during Novartis clinical trial
Setback for Novartis Hepatitis Drug
Slides @ NATAP
Update April 23
Alisporivir (ALV) plus Peg-interferon/Ribavirin (PR) in HCV G1 Treatment-experienced Patients Achieves Primary Endpoint with Superior Efficacy at Treatment Week 12 Compared to Retreatment with PR
Alisporivir plus ribavirin is highly effective as interferon-free or interferon-add-on regimen in previously untreated HCV-G2 or G3 patients: SVR12 results from VITAL-1 Phase 2b study -
EASL Poster
ALISPORIVIR (ALV) PLUS PEG-INTERFERON/RIBAVIRIN (PR) IN HCV G1 TREATMENT-EXPERIENCED PATIENTS ACHIEVES PRIMARY ENDPOINT WITH SUPERIOR EFFICACY AT TREATMENT WEEK 12 COMPARED TO RETREATMENT WITH PR
EASL Poster
ALISPORIVIR PLUS RIBAVIRIN IS HIGHLY EFFECTIVE AS INTERFERON-FREE OR INTERFERON-ADD-ON REGIMEN IN PREVIOUSLY UNTREATED HCV-GT2 OR GT3 PATIENTS: SVR12 RESULTS FROM VITAL-1 PHASE 2B STUDY
On The Blog
EASL-Alisporivir: Pancreatitis Forces Halt to HCV Drug Trial
Roche - Danoprevir
April 19-20
Slides @ NATAP
Updated 23
RAPID AND SUSTAINED ACHIEVEMENT OF UNDETECTABLE HCV RNA DURING TREATMENT WITH RITONAVIR-BOOSTED DANOPREVIR/PEG-IFNα-2A/RBV IN HCV GENOTYPE 1 OR 4 PATIENTS: DAUPHINE WEEK 36 INTERIM ANALYSIS
RITONAVIR SUBSTANTIALLY REDUCES REACTIVE METABOLITE FORMATION OF THE HCV PROTEASE INHIBITOR DANOPREVIR BOTH IN VITRO AND IN VIVO -
Update April 22
RITONAVIR SUBSTANTIALLY REDUCES REACTIVE METABOLITE FORMATION OF THE HCV PROTEASE INHIBITOR DANOPREVIR BOTH IN VITRO AND IN VIVO -
EASl Poster-Danoprevir plus Peg-IFNa-2a/ribavirin for 12weeks results in durable viral suppression and low rates of resistance throughout treatment and follow-up: Results from the ATLAS study
View Abstract
EASL Poster-Low rate of on-treatment resistance to danoprevir boosted by ritonavir (DNVr) combined with Peg-IFNa-2a/ribavirin: 12 week interim analysis from DAUPHINE study
View Abstract
EASL Poster-HIGH SUSTAINED VIROLOGICAL RESPONSE RATES WITH RESPONSE-GUIDED DANOPREVIR PLUS PEGINTERFERON ?LFA-2A (40KD) AND RIBAVIRIN IN TREATMENT-NAIVE, HCV GENOTYPE 1 PATIENTS: ATLAS STUDY FINAL RESULTS
View Abstract
Headlines
Roche reports high rates of sustained viral clearance with investigational hepatitis C treatment danoprevir
On The Blog
EASL-Danoprevir:Roche reports high rates of sustained viral clearance
Medivir - TMC435
April 19-20
Slides @ NATAP-
TMC435 with peginterferon and ribavirin in treatment-experienced HCV genotype 1 patients: the ASPIRE study, a randomised Phase IIb trial
TMC435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon / ribavirin treatment: Virologic analyses of the ASPIRE trial
Headlines
Medivir Hep C Drug Cures 80% of Patients Post-Treatment
Bristol-Myers Expands Hepatitis C Accord With J&J, Medivir
Janssen Creates new Division to Launch TMC435 and Help Conquer Hepatitis C in EMEA
Medivir announces TMC435 in an expanded clinical collaboration
Medivir Hep C Drug Cures 80% of Patients Post-Treatment
On The Blog
EASL-TMC435 Demonstrates Statistically Higher Viral Cure Rates (SVR24) Compared to Placebo in HCV Patients Who Had Failed Prior Treatment
Identix- IDX719
April 19-20
Headlines
Identix: Study Shows Single-Dose Of IDX719 Reduced Hepatitis C Viral Load
On The Blog
Idenix Pharmaceuticals Provides Update on Hepatitis C Clinical Development Programs
Abbott-ABT-450/r, plus ABT-333 and ribavirin
April 19-20
Slides @ NATAP-
A 12-Week Interferon-Free Regimen of ABT-450/r, ABT-072, and Ribavirin was Well Tolerated and Achieved Sustained Virologic Response in 91% Treatment-Naïve HCV IL28B-CC Genotype-1-Infected Subjects
EASL Poster-ABT-450/ritonavir (ABT-450/r) combined with pegylated interferon alpha-2a/ribavirin after 3-day monotherapy in genotype 1 (GT1) HCV-infected treatment-naïve subjects: 12-week sustained virologic
View abstract
Headlines
Abbott Reports Two Hepatitis C Relapses in 'Pilot' Trial
Abbott Hepatitis C Therapy Cures Patients Failed by Other Drugs
On The Blog
EASL-Abbott Presents Positive Results from Interferon-Free Phase 2 "Co-Pilot" Study for the Treatment of Hepatitis C-ABT-450/r, plus ABT-333 and ribavirin
ABT-450/r, ABT-072-ribavirin
April 19-20
On The Blog
EASL-Oral HCV Combo Effective for Genotype One
Boehringer Ingelheim - BI 201335 protease inhibitor and BI 207127 polymerase inhibitor
April 19-20
Slides @ NATAP
Update April 23
SVR4 and SVR12 with an interferon-free regimen of BI 201335 AND BI 207127, +/- ribavirin, in treatment-naïve patients with chronic genotype-1 HCV infection: Interim results of SOUND-C2 -
Update-April 21
The efficacy and safety of the interferon-free combination of BI 201335 and BI 207127 in genotype 1 HCV patients with cirrhosis: Interim analysis from SOUND-C2
EASL Poster-
SVR4 and SVR12 WITH AN INTERFERON-FREE REGIMEN OF BI201335 AND BI207127, +/- RIBAVIRIN, IN TREATMENT-NAÏVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION: INTERIM RESULTS OF SOUND-C2
EASL Poster-CHARACTERIZATION OF HCV NS3 VARIANTS THAT EMERGED DURING VIROLOGIC BREAKTHROUGH AND RELAPSE FROM BI 201335 PHASE II SILEN-C2 STUDY IN PEGIFN/RBV TREATMENT-EXPERIENCED PATIENTS
View Abstract
Headlines
Boehringer Ingelheim Hepatitis C Drugs Cured 82% in Trial
New data from descriptive sub-analysis of patients with compensated liver cirrhosis
On The Blog
EASL-New data from descriptive sub-analysis of patients with compensated liver cirrhosis
EASL- First ever data investigating interferon-free treatment in hepatitis C patients who have liver cirrhosis shows high viral cure rate: protease inhibitor BI 201335 plus the polymerase inhibitor BI 207127 plus ribavirin
Presidio -PPI-383
Update-April 21
On The Blog
EASL-Presidio Announces a New Clinical Candidate, PPI-383, a Novel Pan-Genotypic Non-Nucleoside Polymerase Inhibitor for HCV
Santaris Pharma - Miravirsen
April 19-20
On The Blog
EASL-Final Phase 2a Study Results For Miravirsen Showing Dose-dependent, Prolonged Antiviral Activity In Hepatitis C Patients
EASL
April 19-20
EASL:Hepatitis C-NEW DATA SUGGESTS INTERFERON-FREE THERAPY AROUND THE CORNER
EASL-Peginterferon Lambda Achieved SVR24 Rates Comparable to Peginterferon Alfa with Fewer Side-Effects
HIV and Hepatitis Coverage of the 46th Annual Meeting of the European Association for the Study of the Liver
April 19-20
EASL: International Liver Congress Focuses on Hepatitis C Treatment, Metabolic Liver Disease
Lambda-Bristol-Myers Squibb Company
EASL: Interferon Lambda as Effective as Alfa for Hepatitis C but with Much Better Safety Profile
READ MORE...
Slides @ NATAP
Update April 21
Peginterferon Lambda-1A (Lambda) Compared With Peginterferon Alfa-2A (Alfa) in Treatment- Naive Patients With HCV Genotypes 2 or 3: First SVR24 Results From EMERGE Phase IIb
EASL Poster
PEGINTERFERON LAMBDA-1a (LAMBDA) COMPARED TO PEGINTERFERON ALFA-2A (ALFA) IN TREATMENT-NAÏVE PATIENTS WITH HCV GENOTYPES (G) 2 or 3: FIRST SVR24 RESULTS FROM EMERGE PHASE IIB
On The Blog
EASL-Peginterferon Lambda Achieved SVR24 Rates Comparable to Peginterferon Alfa with Fewer Side-Effects
Vitamin-D
EASL Poster-Chronic and progressive hepatitis due to genotype 1 HCV-infection modify vitamin-D-metabolism
View Abstract
Variations of vitamin D levels in genotype 1 hepatitis C patients undergoing antiviral therapy correlate with stage of fibrosis but not with treatment outcome
View Abstract
Fluvastatin with pegylated interferon/ribavirin
EASL Poster - Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces the viral relapse rate in chronic hepatitis C infected with HCV genotype 1b
View Abstract
Spontaneous Clearance
EASL Poster-FEMALE SEX AND VARIATIONS IN IL28B ARE INDEPENDENTLY ASSOCIATED WITH SPONTANEOUS CLEARANCE OF ACUTE HCV INFECTION
View Abstract
Guidelines
April 19-20
EASL:New Clinical Practice Guideline on Alcoholic Liver Disease Published
2012-New guidelines on the management of hepatocellular carcinoma (HCC).
EASL-April 2012 Revised Clinical Practice Guidelines on the Management of Chronic Hepatitis B
Press release for the International Liver Congress 2012, Barcelona
April 19-20
Documents to download
April 19-20
From Seeking Alpha
From Seeking Alpha
5 Biotech Stocks That Could Soar On New Hepatitis C Drugs -Vertex, Abbott, Achillion, Johnson & Johnson and GlaxoSmithKline
The Street
Headlines
New York Times
Headlines
The Motley Fool
Update-April 21
Seeking Alpha
Update-April 22
The Street
Update April 23
Grading Hep C Stocks Exiting EASL-The future of hepatitis C therapy belongs to interferon-free regimens.
*Index Last Updated On April 23
No comments:
Post a Comment